Concomitant overexpression of the EGFR and erbB‐2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis

No abstract is available for this paper.

• Publication year

  1996

• Venue

  International Journal of Cancer

• Publication date

  1996-02-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-0215(19960220)69:1<17::AID-IJC4>3.0.CO;2-ZPMID 8600053
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Amplification of the epidermal‐growth‐factor‐receptor gene correlates with different growth behaviour in human glioblastoma

  2007cited by this paper
• Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.

  1995cited by this paper
• Expression of HER-2/neu oncoprotein and epidermal growth factor receptor and prognosis in gastric carcinoma.

  1994cited by this paper
• Epidermal growth factor receptor content in human renal cell carcinomas

  1994cited by this paper
• Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy

  1993cited by this paper
• In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis.

  1993cited by this paper
• Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas

  1993cited by this paper
• Amplification and overexpression of the erbB-2 gene in human tumors: its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy.

  1993cited by this paper
• In situ production of TNF-α, IL-1β and IL-2R in ANCA-positive glomerulonephritis

  1993cited by this paper
• The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival.

  1993cited by this paper
• p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases.

  1992cited by this paper
• Expression of HER‐2/neu in renal‐cell carcinoma. Correlation with histologic subtypes and differentiation

  1992cited by this paper
• Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.

  1992cited by this paper
• Modulation of pro-epidermal growth factor, pro-transforming growth factor alpha and epidermal growth factor receptor gene expression in human renal carcinomas.

  1990cited by this paper
• Inverse relationship of epidermal growth factor receptor and HER2/neu gene expression in human renal cell carcinoma.

  1990cited by this paper
• Amplification and overexpression of the epidermal growth factor receptor gene in human renal‐cell carcinoma

  1990cited by this paper
• Expression of transforming growth factor alpha and epidermal growth factor receptor messenger RNA in neoplastic and nonneoplastic human kidney tissue.

  1989cited by this paper
• Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers.

  1989cited by this paper
• Enhanced expression of c-myc and epidermal growth factor receptor (C-erbB-1) genes in primary human renal cancer.

  1988cited by this paper
• Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics.

  1986cited by this paper
• Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

  1985cited by this paper
• Letter: Vitamin-C-induced hyperoxaluria.

  1976cited by this paper

• Involvement of Epidermal Growth Factor Receptor (EGFR) Signaling in Renal Cell Carcinoma Progression and Therapeutic Implication

  2025cites this paper
• An integrative analysis reveals cancer risk associated with artificial sweeteners

  2025cites this paper
• Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics

  2025cites this paper
• Recent progress in molecular classification of phaeochromocytoma and paraganglioma.

  2024cites this paper
• ERBB2 is a potential diagnostic and prognostic biomarker in renal clear cell carcinoma

  2024cites this paper
• Immunotherapy in renal cell carcinoma.

  2023influential citation
• Telomerase RNA TERC and the PI3K-AKT pathway form a positive feedback loop to regulate cell proliferation independent of telomerase activity

  2022cites this paper
• Single-nuclei and bulk-tissue gene-expression analysis of pheochromocytoma and paraganglioma links disease subtypes with tumor microenvironment

  2022cites this paper
• The Role of ERBB Signaling Pathway-Related Genes in Kidney Renal Clear Cell Carcinoma and Establishing a Prognostic Risk Assessment Model for Patients

  2022cites this paper
• Identification of HCC-Related Genes Based on Differential Partial Correlation Network

  2021cites this paper
• LDLR promotes growth and invasion in renal cell carcinoma and activates the EGFR pathway.

  2021cites this paper
• Prognostic Impact of Membranous/Nuclear Epidermal Growth Factor Receptor Localization in Clear Cell Renal Cell Carcinoma

  2021cites this paper
• Identification of novel targets of miR-622 in hepatocellular carcinoma reveals common regulation of cooperating genes and outlines the oncogenic role of zinc finger CCHC-type containing 11

  2021cites this paper
• Combined De-Repression of Chemoresistance Associated Mitogen-Activated Protein Kinase 14 and Activating Transcription Factor 2 by Loss of microRNA-622 in Hepatocellular Carcinoma

  2021cites this paper
• The lncRNA MEG3 mediates renal cell cancer progression by regulating ST3Gal1 transcription and EGFR sialylation

  2020cites this paper
• Expression of EGFR family and p53 in a patient with Synchronous Primary Endometrial Adenocarcinoma and Clear Cell Renal Carcinoma: a Case Report

  2018cites this paper
• ONCOMARKERS IN TUMORS OF RENAL PARENCHYMA

  2018cites this paper
• MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma.

  2017cites this paper
• MicroRNA-34a/EGFR axis plays pivotal roles in lung tumorigenesis

  2017cites this paper
• Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer

  2017cites this paper
• RIN1 promotes renal cell carcinoma malignancy by activating EGFR signaling through Rab25

  2017cites this paper
• MiR-514 a-3 p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma

  2017cites this paper
• Nanotechnology in Drug Delivery 21 2 Role of nanoparticles in targeted drug delivery system

  2016cites this paper
• Application of single-cell RNA sequencing in optimizing a combinatorial therapeutic strategy in metastatic renal cell carcinoma

  2016cites this paper
• EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma.

  2016cites this paper
• Bone Metastasis from Renal Cell Carcinoma

  2016cites this paper
• MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor.

  2016cites this paper
• Prognostic impact of epidermal growth factor receptor on clear cell renal cell carcinoma: Does it change with different expression patterns?

  2016cites this paper
• HER2 EXPRESSION IN RENAL CELL CARCINOMA

  2015cites this paper
• EGFR and HER2: Relevance in Renal Cell Carcinoma

  2015cites this paper
• HER 2 EXPRESSION IN RENAL CELL CARCINOMA

  2015cites this paper
• HER2/neu: an increasingly important therapeutic target. Part 2: Distribution of HER2/neu overexpression and gene amplification by organ, tumor site and histology

  2014cites this paper
• Photothermolysis mediated by gold nanorods modified with EGFR monoclonal antibody induces Hep-2 cells apoptosis in vitro and in vivo

  2014cites this paper
• Part 2 : Distribution of HER 2 / neu overexpression and gene amplification by organ , tumor site and histology

  2014cites this paper
• Multifunctional Polymeric Micelles for Drug Delivery and Therapeutics

  2013cites this paper
• Detection of Deregulated Modules Using Deregulatory Linked Path

  2013cites this paper
• Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis

  2012influential citation
• Prognostic Factors in Renal Cell Carcinoma: An Evaluation of T-Stage, Histopathological Grade, p53, Ki-67, COX-2, and Her-2 Expressions

  2012cites this paper
• Lapatinib and renal cell carcinoma

  2012cites this paper
• EGFR Proteinexpression und genetische Alterationen in Nierenzellkarzinomen

  2012cites this paper
• Redacted for Privacy

  2012cites this paper
• Malignant Renal Tumors

  2012cites this paper
• EGFR protein overexpression correlates with chromosome 7 polysomy and poor prognostic parameters in clear cell renal cell carcinoma

  2012cites this paper
• Epidermal growth factor receptor protein expression and genomic alterations in renal cell carcinoma

  2012cites this paper
• A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma

  2011cites this paper
• EGF receptor inhibitors

  2011cites this paper
• EGFR and HER3 mRNA expression levels predict distant metastases in locally advanced rectal cancer

  2011cites this paper
• Amplification of epidermal growth factor receptor gene in renal cell carcinoma.

  2010cites this paper
• Review: Targeted therapy in renal cancer

  2009cites this paper
• The EGFR protein expression and the gene copy number changes in renal cell carcinomas

  2009cites this paper
• Expression and prognostic value of LRIG1 and the EGF-receptor family in renal cell and prostate cancer

  2009cites this paper
• New series No 1271

  2009cites this paper
• Studies of LRIG1 and the ERBB receptor family in breast and colorectal cancer

  2009cites this paper
• Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.

  2008cites this paper
• Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells.

  2008cites this paper
• Targeted therapy for advanced renal cell cancer: cytokines and beyond.

  2008cites this paper
• Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

  2008cites this paper
• Fatty acid synthase over expression is an indicator of tumor aggressiveness and poor prognosis in renal cell carcinoma.

  2008cites this paper
• Anti-Epidermal Growth Factor Receptor Strategies for Advanced Breast Cancer

  2008cites this paper
• Epithelial growth factor receptor (EGFR) pathway and renal cell carcinoma

  2007cites this paper
• Reduction of cell proliferation induced by PD166866: an inhibitor of the basic fibroblast growth factor.

  2007cites this paper
• The prognostic significance of epidermal growth factor receptor expression in clear-cell renal cell carcinoma: a call for standardized methods for immunohistochemical evaluation.

  2007cites this paper
• Renal cell carcinoma bone metastasis—elucidating the molecular targets

  2007cites this paper
• Her-2/neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes1

  2006cites this paper
• Inhibition of HER-2(neu/ErbB2) restores normal function and structure to polycystic kidney disease (PKD) epithelia.

  2006cites this paper
• Clinical advancement of EGFR inhibitors in cancer therapy.

  2006cites this paper
• EGFR function and detection in cancer therapy.

  2006cites this paper
• Current status and perspective of antiangiogenic therapy for cancer: urinary cancer

  2006cites this paper
• Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation.

  2006cites this paper
• A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors

  2006cites this paper
• Her-2 / neu-derived Peptides Are Tumor-associated Antigens Expressed by Human Renal Cell and Colon Carcinoma Lines and Are Recognized by in Vitro Induced Specific Cytotoxic T Lymphocytes 1

  2006cites this paper
• Targeted Therapy for Renal Cell Carcinoma: A New Therapeutic Paradigm

  2006cites this paper
• Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis

  2006cites this paper
• APhase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combinationwith Docetaxel in Patients with Advanced Solid Tumors

  2006cites this paper
• A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma

  2006cites this paper
• Studies on decolorization process for rhEGF as cosmetic ingredient

  2005cites this paper
• EGFR mRNA is Upregulated, but Somatic Mutations of the Gene are Hardly Found in Renal Cell Carcinoma in Japanese Patients

  2005cites this paper
• Molecular mechanisms of drug resistance in renal cancer

  2005cites this paper
• Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma

  2005cites this paper
• Antiangiogenic Effect of ZD1839 against Murine Renal Cell Carcinoma (RENCA) in an Orthotopic Mouse Model

  2005cites this paper
• Partial purification properties of human epidermal growth factor from recombinant Escherichia coli by expanded bed adsorption

  2005cites this paper
• A Phase II Trial of Gefitinib ( Iressa , ZD 1839 ) in Stage IV and Recurrent Renal Cell Carcinoma

  2004cites this paper
• Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma

  2004cites this paper
• Epidermal growth factor receptor: a promising target in solid tumours.

  2004cites this paper
• Treatment of recurrent or metastatic renal cell carcinoma

  2004cites this paper
• A Phase II Trial of Gefitinib (Iressa, ZD1839) in Stage IV and Recurrent Renal Cell Carcinoma

  2004cites this paper
• Differential expression of activator protein-2 isoforms in renal cell carcinoma.

  2004cites this paper
• Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

  2004cites this paper
• Advances in immune-based therapies of renal cell carcinoma

  2004cites this paper
• Prognostic Factors in Renal Cell Carcinoma

  2004cites this paper
• Anti-angiogenic Effect of Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(ZD1839) against Murine Renal Cell Carcinoma Orthotopic Model

  2004cites this paper
• Analyse der Prostaglandin E2-induzierten Immunsuppression von Monozyten durch Tumorzellen

  2004cites this paper
• Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.

  2003cites this paper
• Renal Cell Carcinoma Bone Metastasis: Epidermal Growth Factor Receptor Targeting

  2003cites this paper
• [Expression of epidermal growth factor receptor and its ligands in other malignant tumor pathologies].

  2003cites this paper
• [EGF receptors in urological cancer. Molecular basis and therapeutic involvements].

  2003cites this paper
• Renal-cell carcinoma: tumour markers, T-cell epitopes, and potential for new therapies.

  2003cites this paper
• Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer

  2003cites this paper
• CD44 associates with EGFR and erbB2 in metastasizing mammary carcinoma cells.

  2002cites this paper
• CD44 Associates With EGFR and erbB2 in Metastasizing Mammary Carcinoma Cells

  2002cites this paper